- Home
- CZNC vs PRQR Comparison
CZNC vs PRQR Comparison
Compare CZNC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | PRQR |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.9M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CZNC | PRQR |
|---|---|---|
| Price | $20.65 | $2.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $22.00 | $8.14 |
| AVG Volume (30 Days) | 76.3K | ★ 634.1K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | $18,859,556.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $7.18 | $19.56 |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $1.07 |
| 52 Week High | $22.68 | $3.10 |
Technical Indicators
Market Signals| Indicator | CZNC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 49.04 |
| Support Level | $20.46 | $2.03 |
| Resistance Level | $22.25 | $2.25 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 21.70 | 37.36 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.